NCT02475551View on ClinicalTrials.gov

Study to Evaluate the Safety, Tolerability, Efficacy and PK of IdeS in Kidney Transplantation

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

October 31, 2016

Study Completion Date

October 31, 2016

Conditions
End Stage Kidney Disease
Interventions
DRUG

IdeS

Intravenous infusion

Trial Locations (1)

22007

Hansa Medical AB, Lund

Sponsors

Lead Sponsor

Hansa Biopharma AB
All Listed Sponsors
collaborator

Uppsala University Hospital

OTHER

collaborator

Karolinska Institutet

OTHER

lead

Hansa Biopharma AB

INDUSTRY

NCT02475551 - Study to Evaluate the Safety, Tolerability, Efficacy and PK of IdeS in Kidney Transplantation | Biotech Hunter | Biotech Hunter